← back to search

Jens Neumann

Hamburg Institute for Therapy Research · DE
🔎 Find collaborators in Oncology · Pathology and Forensic Medicine →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Lung Cancer Treatments and Mutations, and Gastric Cancer Management and Outcomes.
h-index
43
citations
9,327
works
410
NIH funding
primary concept
Medicine
email

Recent publications

Subtype-Dependent Expression Patterns of Core Hippo Pathway Components in Thymic Epithelial Tumors (TETs): An RT-qPCR Study.
2026cited by 0position: contributordoi
Development and Release of the Munich UICC Staging Tool (MUST): Advancing UICC Staging in Real-World Data With Insights From Pancreatic and Stomach Cancer.
2026cited by 0position: contributordoi
German S2k-guideline on diagnostics, treatment and surveillance of low-grade appendiceal mucinous neoplasms (LAMN)
European Journal of Cancer 2025cited by 3position: middledoi
Subtype-Dependent Hippo Pathway Deregulation in Thymic Epithelial Tumors (TETs): A RT-qPCR-Based Expression Analysis
2025cited by 0position: contributordoi
Concordance of laboratory assays for claudin 18.2 in gastric cancer tissue samples: independent proficiency testing and a descriptive non-interventional study.
2025cited by 0position: contributordoi
Supplementary Data from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary table S3 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary table S1 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary table S2 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary Data from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary table S4 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Supplementary video file from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2025cited by 0position: contributordoi
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)
ESMO Open 2024cited by 10position: middledoi
Identification of a gene expression signature associated with brain metastasis in colorectal cancer
Clinical & Translational Oncology 2024cited by 8position: lastdoi
Tumor board simulation improves interdisciplinary decision-making in medical students
Journal of Cancer Research and Clinical Oncology 2024cited by 2position: middledoi
Comparative transcriptomic analyses reveal activation of the epithelial-mesenchymal transition program in non-metastasizing low grade pseudomyxoma peritonei
Pathology - Research and Practice 2024cited by 2position: middledoi
Molecular characteristics of microsatellite stable early-onset colorectal cancer as predictors of prognosis and immunotherapeutic response
npj Precision Oncology 2023cited by 24position: middledoi
Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
Cancer Research Communications 2023cited by 5position: middledoi
Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer.
2023cited by 5position: contributordoi
Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.
2023cited by 5position: contributordoi
On the trail of a ticking bomb: an unusual case of gastrointestinal bleeding in a young adult.
2023cited by 0position: contributordoi
Supplementary Figure S2 from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
2023cited by 0position: contributordoi
Data from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
2023cited by 0position: contributordoi
TABLE 1 from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
2023cited by 0position: contributordoi
Supplementary table S2 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2023cited by 0position: contributordoi
Supplementary table S4 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2023cited by 0position: contributordoi
Supplementary table S1 from SMAD4 Loss Induces c-MYC–Mediated NLE1 Upregulation to Support Protein Biosynthesis, Colorectal Cancer Growth, and Metastasis
2023cited by 0position: contributordoi
Supplementary Table S5 from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
2023cited by 0position: contributordoi
Data from Development and validation of a 15-gene expression signature with superior prognostic ability in stage II colorectal cancer
2023cited by 0position: contributordoi
Supplementary Table S2 from Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 81 papers (2021–2026)Heiko Hermeking · Taipei Institute of Pathology74 papers (2020–2025)Matjaz Rokavec · Taipei Institute of Pathology72 papers (2022–2025)Elif Özcan · Ludwig-Maximilians-Universität München48 papers (2023–2023)Thomas Kirchner · FH Aachen35 papers (2012–2024)Frederick Klauschen · Institute of Clinical Cancer Research30 papers (2021–2025)Dieter Saur · German Cancer Research Center25 papers (2022–2025)Thomas Kirchner · German Cancer Research Center24 papers (2022–2025) · 24 papers (2022–2025) · 24 papers (2022–2025)Markus Tschurtschenthaler · TUM Klinikum24 papers (2022–2025)Peter Jung · Boehringer Ingelheim (Austria)24 papers (2022–2025)Miguel Silva · IPO Porto24 papers (2022–2025)Leon P. Loevenich · German Centre for Cardiovascular Research24 papers (2022–2025)Andreas Jung · University of Lübeck17 papers (2012–2022)Volker Heinemann · LMU Klinikum16 papers (2012–2024)Martin K. Angele · LMU Klinikum12 papers (2015–2024)Jens Werner · University Hospital Heidelberg11 papers (2015–2024)Jörg Kumbrink · German Cancer Research Center11 papers (2020–2024)Sebastian Stintzing · German Cancer Research Center10 papers (2015–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Pathology and Forensic Medicine →